written on 13.06.2014

Vivus hits Actavis with Qsymia patent-infringement lawsuit


Weak Qsymia sales have been the all-important issue for Vivus since the highly anticipated obesity therapy stumbled out of the gate, inspiring an all-out proxy war that wreaked havoc on the company's boardroom. And the California company isn't about to cede what market share it does have to Actavis–at least, not without a fight.